Chemistry:Runcaciguat

From HandWiki
Short description: Chemical compound
Runcaciguat
Runcaciguat.svg
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC23H22Cl2F3NO3
Molar mass488.33 g·mol−1
3D model (JSmol)

Runcaciguat is a soluble guanylate cyclase stimulator developed by Bayer for non-proliferative diabetic retinopathy and chronic kidney disease.[1][2][3]

References

  1. Bénardeau, Agnès; Kahnert, Antje; Schomber, Tibor; Meyer, Jutta; Pavkovic, Mira; Kretschmer, Axel; Lawrenz, Bettina; Hartmann, Elke et al. (December 2021). "Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease". Naunyn-Schmiedeberg's Archives of Pharmacology 394 (12): 2363–2379. doi:10.1007/s00210-021-02149-4. PMID 34550407. 
  2. Hahn, Michael G.; Lampe, Thomas; El Sheikh, Sherif; Griebenow, Nils; Woltering, Elisabeth; Schlemmer, Karl-Heinz; Dietz, Lisa; Gerisch, Michael et al. (13 May 2021). "Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)". Journal of Medicinal Chemistry 64 (9): 5323–5344. doi:10.1021/acs.jmedchem.0c02154. PMID 33872507. 
  3. Nelissen, Ellis; Possemis, Nina; Van Goethem, Nick P.; Schepers, Melissa; Mulder-Jongen, Danielle A. J.; Dietz, Lisa; Janssen, Wiebke; Gerisch, Michael et al. (4 March 2022). "The sGC stimulator BAY-747 and activator runcaciguat can enhance memory in vivo via differential hippocampal plasticity mechanisms" (in en). Scientific Reports 12 (1): 3589. doi:10.1038/s41598-022-07391-1. ISSN 2045-2322. PMID 35246566. Bibcode2022NatSR..12.3589N.